Astorg’s acquisition of biotechnology ingredients provider Solabia was supported by financing from Goldman Sachs and Arcmont, according to market sources.
The lenders provided a roughly €600 million financing package, priced at around E+475 bps, with a 99 OID.
The financing includes a unitranche loan of around €410-415 million and a holdco PIK facility of roughly €100 million. There is also an undrawn facility, sources added.
The lenders refinanced an existing loan with new seven-year portable debt. The company was marketed at EBITDA of roughly €65 million, sources said.
Goldman Sachs was an incumbent lender. Astorg is in discussions with a couple more lenders to take a small piece of the unitranche, sources added.
Astorg on May 7 agreed to acquire a majority stake in Solabia from TA Associates.
Solabia specializes in natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, food and clinical testing industries. Headquartered in Paris, the company operates 11 manufacturing sites and eight R&D labs worldwide.
Nata Serenko/Getty Images
Learn about our editorial standards.